BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:FDCSP+ fibroblasts predict response to cancer immunotherapy - Dr D
 aniele Biasci
DTSTART:20210225T131000Z
DTEND:20210225T140000Z
UID:TALK157345@talks.cam.ac.uk
CONTACT:Janet Gibson
DESCRIPTION:Immune checkpoint inhibitors (ICI) are a class of anti-cancer 
 drugs that work by potentiating the patient's immune response. ICI deliver
 ed impressive clinical benefits in cancer types previously considered untr
 eatable\, such as metastatic melanoma. Unfortunately\, only some patients 
 respond to this type of immunotherapy\, for reasons that remain substantia
 lly unknown. Despite our incomplete understanding of this phenomenon\, it 
 has been observed that the presence of certain cell types might characteri
 ze immunotherapy-responsive tumours. For instance\, infiltration of immune
  cells (i.e. T and B cells) has been associated with an increased probabil
 ity of ICI response. On the other hand\, an abundance of stromal cells (i.
 e. cancer-associated fibroblasts\, or CAFs) has been associated with a lac
 k of response and poor clinical outcomes. As a consequence\, targeting CAF
 s has been proposed as a possible strategy to increase the efficacy of can
 cer immunotherapy. Surprisingly\, we recently identified a subpopulation o
 f CAFs associated with ICI response independently of T and B cells. This o
 bservation might help to identify ICI responsive tumours and has important
  consequences for therapeutic strategies targeting fibroblasts in cancer i
 mmunotherapy.\n
LOCATION:ONLINE - Email organiser to request link - Details to be sent by 
 email
END:VEVENT
END:VCALENDAR